Your email has been successfully added to our mailing list.

×
0.160919540229885 0.160919540229885 0.160919540229885 0.160919540229885 0.160919540229885 0.160919540229885 0.0801724137931036 0.0201149425287357
Stock impact report

Novelion Therapeutics Announces Marketing Authorization for MYALEPTA® (metreleptin) in the European Union to Treat Generalized and Partial Lipodystrophy

NOVELION THERAPEUTICS INC COMMON SHARES (NVLN) 
Last novelion therapeutics inc common shares earnings: 5/7 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.novelion.com
Company Research Source: GlobeNewswire
VANCOUVER, British Columbia, July 31, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to delivering new standards of care for people living with rare and underserved metabolic diseases, today announced that the European Commission (EC) has granted marketing authorization for MYALEPTA® (metreleptin), as an adjunct to diet, as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients with confirmed congenital generalized LD (Berardinelli-Seip syndrome) or acquired generalized LD (Lawrence syndrome) in adults and children 2 years of age and above; or with confirmed familial partial LD or acquired partial LD (Barraquer-Simons syndrome), in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control. MYALEPTA, a recombinant analog of human leptin, is the first and only licensed treatment in Europe indicated as an adjunct to Show less Read more
Impact Snapshot
Event Time:
NVLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for NVLN alerts
Opt-in for
NVLN alerts

from News Quantified
Opt-in for
NVLN alerts

from News Quantified